Orchestra BioMed Holdings (OBIO) FCF Margin (2022 - 2025)
Historic FCF Margin for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to 1725.9%.
- Orchestra BioMed Holdings' FCF Margin fell 3309700.0% to 1725.9% in Q3 2025 from the same period last year, while for Sep 2025 it was 2157.31%, marking a year-over-year decrease of 3373600.0%. This contributed to the annual value of 1927.48% for FY2024, which is 2533900.0% down from last year.
- Per Orchestra BioMed Holdings' latest filing, its FCF Margin stood at 1725.9% for Q3 2025, which was down 3309700.0% from 1861.36% recorded in Q2 2025.
- In the past 5 years, Orchestra BioMed Holdings' FCF Margin ranged from a high of 620.21% in Q1 2022 and a low of 5392.89% during Q4 2024
- Its 4-year average for FCF Margin is 1926.33%, with a median of 1725.9% in 2025.
- Per our database at Business Quant, Orchestra BioMed Holdings' FCF Margin plummeted by -33897600bps in 2023 and then surged by 10635400bps in 2024.
- Quarter analysis of 4 years shows Orchestra BioMed Holdings' FCF Margin stood at 797.64% in 2022, then crashed by -425bps to 4187.4% in 2023, then decreased by -29bps to 5392.89% in 2024, then soared by 68bps to 1725.9% in 2025.
- Its FCF Margin stands at 1725.9% for Q3 2025, versus 1861.36% for Q2 2025 and 1927.19% for Q1 2025.